The COVID-19 outbreak triggered an unprecedented demand shock for crude oil, resulting in a 40% decline in price in the first quarter of 2020.

In this report I update my objectives and include several buy recommendations in the biotech sphere.

With great risk comes great reward. The truly great investors understand the risk/reward ratio and aren't afraid to take a calculated chance. How do we mitigate that risk?